Amgen beefs up cardio pipeline, adding a $673M RNAi deal with Arrowhead
Last May, Arrowhead Pharmaceuticals CEO Chris Anzalone turned up at a scientific conference in Nashville to talk up some of the company’s preclinical RNAi work on cardiovascular disease.
Working with mice and monkeys, investigators for the biotech demonstrated that a subcutaneously delivered therapy dubbed ARC-LPA demonstrated some real potential for knocking down levels of apolipoprotein(a), a key component of lipoprotein(a), or Lp(a).
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.